- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04023318
The BMI Project (Body, Mind, Inflammation)
A Novel Integrated Lifestyle Intervention to Reduce Obesity and Inflammation Among Emerging Adults
Obesity and chronic inflammation influence the development and progression of many types of cancer. These conditions share several of the same causes, including physical inactivity, poor nutrition, stress, and insufficient sleep. Emerging adulthood (ages 18-25) represents an important developmental period in which to address behaviors and psychological variables that affect both weight status and inflammation. At least 40% of emerging adults have overweight/obesity, and this transition from adolescence to early adulthood is associated with significant increases in fast food consumption, decreases in physical activity, unpredictable sleep schedules, and alarmingly high rates of depression and perceived stress.
Despite this high risk for obesity, very few weight loss interventions are designed specifically for emerging adults. Preliminary findings from weight loss interventions targeting this population have shown some promise, but generally produce modest outcomes with less consistent effects than programs in older adults. Depression and stress have been found to interfere with weight loss among emerging adults, and may be in part responsible for poorer outcomes. This proposal will develop and test an Integrated Lifestyle Intervention (ILI) that comprehensively addresses both psychological distress and traditional weight management targets. This novel approach has not been tested before and has the potential not only to enhance weight loss outcomes in this high risk population, but also to produce reductions in markers of inflammation beyond those achievable by weight loss alone.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23219
- Virginia Commonwealth University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age between 18 and 25 years
- Body Mass Index between 25 and 45 kg/m2
Exclusion Criteria:
- Currently pregnant or lactating; pregnancy in the last 6 months or plans to become pregnant in the next 6 months
- Type 1 or type 2 diabetes
- Any uncontrolled medical conditions that could make it unsafe to participate in unsupervised exercise
- Medical conditions associated with chronic inflammation
- Inability to read, understand and speak English
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Integrated Lifestyle Intervention
|
This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population.
The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes.
As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control.
Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease.
Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach.
Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of sessions attended throughout the intervention period
Tidsram: 4 months
|
Attendance at in-person treatment sessions is one critical metric for demonstrating feasibility and will be tracked throughout the intervention period.
|
4 months
|
|
Number of days self-monitoring weight in LoseIt
Tidsram: 4 months
|
Self-monitoring of weight is a critical metric for demonstrating feasibility and will be tracked throughout the intervention period.
|
4 months
|
|
Number of days self-monitoring weight-related behaviors in LoseIt
Tidsram: 4 months
|
Self-monitoring of weight-related behaviors (e.g., diet and physical activity) is a critical metric for demonstrating feasibility and will be tracked throughout the intervention period.
|
4 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in diet
Tidsram: Baseline and 4 months
|
Dietary change will be assessed using the Diet History Questionnaire III (DHQ-III), a 166-item adaptive questionnaire developed by NCI which maps on to dietary intervention targets (e.g., saturated fat, alcohol, sugar, fiber, sodium), as well as a measure of overall diet.
|
Baseline and 4 months
|
|
Change in physical activity
Tidsram: Baseline and 4 months
|
Participants will report their physical activity using the 6-item Paffenbarger Physical Activity Questionnaire, which yields estimates of minutes spent in moderate-to-vigorous physical activity.
|
Baseline and 4 months
|
|
Change in sleep
Tidsram: Baseline and 4 months
|
The EARLY Trials Common Elements Sleep Questionnaire (8 items) will be administered that asks about duration of sleep and problems encountered during sleep (e.g.
snoring).
|
Baseline and 4 months
|
|
Percent Weight Change
Tidsram: Baseline and 4 months
|
Weight will be measured in light clothes, without shoes, on calibrated Tanita BWB-800S scales.
Percent change of initial body weight will be calculated using baseline and 4 month weights.
|
Baseline and 4 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Jessica LaRose, PhD, Virginia Commonwealth University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MCC-18-14509
- HM20015075 (Annan identifierare: Virginia Commonwealth University IRB)
- NCI-2019-04792 (Annan identifierare: National Cancer Institute)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .